Second-line chemotherapy for advanced biliary cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new form of chemotherapy (liposomal irinotecan, given with other drugs) for people whose bile duct, gallbladder, or other biliary cancer has advanced after first-line treatment. The goal is to see if this second-line combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the bile ducts, gallbladder, or other bile system (biliary tract).
- Your cancer got worse or you couldn't handle the side effects after one prior chemotherapy combination.
- You have at least one tumor that can be measured on a scan (CT or MRI).
- You are physically well enough to do light activities (ECOG score 0 or 1).
- You have not been treated before with irinotecan, 5-fluorouracil (5-FU), or drugs that block blood vessel growth.
- You do not have serious heart problems, uncontrolled high blood pressure, bleeding in the stomach or intestines, or a recent blood clot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
This trial tests a new combination of an oncolytic virus plus lenvatinib and toripalimab (immunotherapy drugs) compared with the standard chemotherapy FOLFOX for advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps people whose cancer has progressed after one line of treatment.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has grown despite previous treatment. The goal is to see if this new combination can help shrink tumors or slow down the cancer.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.